thalidomide has been researched along with naloxone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benevides, VM; Brito, GA; Cunha, FQ; Ferreira, SH; Poole, S; Ribeiro, RA; Vale, ML | 1 |
| Dehpour, AR; Ejtemaei-Mehr, S; Jahanabadi, S; Khan, MI; Momeny, M; Ostadhadi, S; Sameem, B; Zarrinrad, G | 1 |
| Alonso-Pérez, A; Bravo, SB; Crespo-Golmar, A; Franco-Trepat, E; Gómez, R; Gualillo, O; Guillán-Fresco, M; Jorge-Mora, A; López-Fagúndez, M; Pazos-Pérez, A | 1 |
1 review(s) available for thalidomide and naloxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for thalidomide and naloxone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation.
Topics: Analgesics; Animals; Arthralgia; Arthritis, Experimental; Chemokine CXCL1; Chemokines, CXC; Exudates and Transudates; Immunohistochemistry; Immunosuppressive Agents; Injections, Intraperitoneal; Interleukin-1; Interleukin-6; Knee Joint; Male; Naloxone; Narcotic Antagonists; Rats; Rats, Wistar; Synovial Membrane; Thalidomide; Tumor Necrosis Factor-alpha; Zymosan | 2006 |
Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways.
Topics: Animals; Cell Line, Tumor; Central Nervous System Agents; Hippocampus; Humans; Male; Mice; Morphine; Morphine Dependence; Naloxone; Nitric Oxide; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Substance Withdrawal Syndrome; Thalidomide | 2018 |
Repurposing drugs to inhibit innate immune responses associated with TLR4, IL1, and NLRP3 signaling in joint cells.
Topics: Chondrocytes; Drug Repositioning; Humans; Immunity, Innate; Inflammasomes; Interleukin-1; Naloxone; NLR Family, Pyrin Domain-Containing 3 Protein; Osteoarthritis; Proteome; Proteomics; Receptors, Interleukin-1; Thalidomide; Toll-Like Receptor 4 | 2022 |